Tomer Mark MD

PubMed

• Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
  Zachary M Avigan, Suzanne Arinsburg, Darren Pan, Tomer Mark, Christopher Fausel
  Bone Marrow Transplantation. 2025-01-01
• Single-Cell RNA Sequencing before and after Light Chain Escape Reveals Intrapatient Multiple Myeloma Subpopulations with Divergent Osteolytic Gene Expression.
  Denis Ohlstrom, Zachary J Walker, Abhishek Pandey, Lorraine N Davis, Krysta L Engel
  Cancer Research Communications. 2025-01-01
• 4 citations
  Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
  Zachary M Avigan, Suzanne Arinsburg, Darren Pan, Tomer Mark, Christopher Fausel
  Bone Marrow Transplantation. 2024-10-01

Journal Articles

• Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Sur...  
  Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, ..., Biol Blood Marrow Transplant, 1/24/2017
• Cellular Proliferation by Multiplex Immunohistochemistry Identifies High Risk Multiple Myeloma in Newly Diagnosed, Treatment Naïve Patients  
  Ely S, Forsberg P, Ousansafi I, Rossi A, Modin A, Pearse R, Pekle K, Perry A, Coleman M, Jayabalan D, Di Liberto M, Chen-Kiang S, Niesvizky R, Mark TM, Clin Lymphoma Myeloma Leuk, 1/20/2017
• Granulocyte Colony-Stimulating Factor Use after Autologous Peripheral Blood Stem Cell Transplantation: Comparison of Two Practices  
  Singh AD, Parmar S, Patel K, Shah S, Shore T, Gergis U, Mayer S, Phillips A, Hsu JM, Niesvizky R, Mark TM, Pearse R, Rossi A, van Besien K, Biol Blood Marrow Transplant, 1/20/2017

Books/Book Chapters

• Wintrobe’s Atlas of Clinical Hematology 
  Chapter: Plasma Cell Disorders. 
  Mark T, Schechter GPLippincott Williams & WilkinsEdition 2nd,2017
• Knowles’ Neoplastic Hematopathology 
  Chapter: B-cell immunoproliferative disorders, including multiple myeloma and primary amyloidosis. 
  Ely S, Niesvizky R, Mark TLippincott Williams & WilkinsEdition 3rd,2013
• Love, Olivia. 
  Chin O, Mark TWestBow Press2012

Abstracts/Posters

• Broad Efficacy of the Translation Inhibitor Omacetaxine in Relapsed/Refractory Multiple Myeloma Samples
  Tomer M Mark, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Efficacy and Safety of Daratumumab, Bortezomib and Dexamethasone (Dvd) Versus Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Upda...
  Weisel K, Lentzsch S, Mateos MV, Hungria V, Munder M, Nooka A, Mark T, Quach H, Scott EC, Lee JJ, Sonneveld P, Casneuf T, Chiu C, Qin X, Amin H, Thiyagarajah P, Schect..., Haematologica; European Hematology Association Meeting, 1/1/2017
• Use of Montelukast to Reduce Infusion Reactions in an Early Access Treatment Protocol of Daratumumab in United States Patients with Relapsed or Refractory Multiple Mye...
  Chari A, Mark TM, Krishnan A, Stockerl-Goldstein K, Usmani SZ, Londhe A, Etheredge D, Parros H, Fleming S, Liu BL, Freeman S, Ukropec J, Lin T, Nooka AK, American Society of Hematology, 1/1/2016

Lectures

• Best of Myeloma at ASH 2016. 
  University of Colorado - 1/27/2017
• In the relapsed patient, what would be the ideal treatment? 
  New York, NY - 1/26/2017
• New Drugs in Multiple Myeloma 
  University of Colorado, Anschutz Medical Campus - 1/9/2017